Associated Papers
Identifying active and inhibitor-resistant MGMT variants for gene therapy.
Cheong A et al.
American Journal of Human Genetics, 2025
SMARCAD1-mediated recruitment of the DNA mismatch repair protein MutLα to MutSα on damaged chromatin induces apoptosis in human cells.
Takeishi Y et al.
The Journal of Biological Chemistry, 2020
Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.
Yasuda M et al.
Molecular Genetics and Metabolism, 2019
Tumor-associated mutations in O⁶ -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality.
Lamb KL et al.
Molecular Carcinogenesis, 2014
Gene therapy for chronic granulomatous disease.
Ryser MF et al.
Expert Opinion on Biological Therapy, 2007
Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection.
Richard E et al.
Gene Therapy, 2004
Gene therapy for chronic granulomatous disease.
Barese CN et al.
Expert Opinion on Biological Therapy, 2004
Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: lack of copy number selection by drug treatment.
Zielske SP et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy, 2004
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
Ma S et al.
British Journal of Cancer, 2003
A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines.
Richard E et al.
The Journal of Gene Medicine, 2003
Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
Bowman JE et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy, 2003
A SIN lentiviral vector containing PIGA cDNA allows long-term phenotypic correction of CD34+-derived cells from patients with paroxysmal nocturnal hemoglobinuria.
Robert D et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy, 2003
[Mutation of human O6-alkylguanine-DNA alkyltransferase confers resistance to O6-benzylguanine].
Wan Y et al.
Zhonghua Zhong Liu Za Zhi [chinese Journal of Oncology], 2000
Protection of hematopoietic cells against combined O6-benzylguanine and chloroethylnitrosourea treatment by mutant forms of O6-methylguanine DNA methyltransferase.
Williams DA et al.
Bone Marrow Transplantation, 2000
Redesigning the substrate specificity of human O(6)-alkylguanine-DNA alkyltransferase. Mutants with enhanced repair of O(4)-methylthymine.
Encell LP et al.
Biochemistry, 1999
Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.
Maze R et al.
The Journal of Pharmacology and Experimental Therapeutics, 1999